Clinical Trials
4 trialsNCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT00423254 2010-08-03
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Phase 1 Completed